- Home
- CTSH vs ONC Comparison
CTSH vs ONC Comparison
Compare CTSH & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTSH
- ONC
- Stock Information
- Founded
- CTSH 1994
- ONC 2010
- Country
- CTSH United States
- ONC Switzerland
- Employees
- CTSH N/A
- ONC N/A
- Industry
- CTSH EDP Services
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- CTSH Technology
- ONC Health Care
- Exchange
- CTSH Nasdaq
- ONC Nasdaq
- Market Cap
- CTSH 34.1B
- ONC 37.2B
- IPO Year
- CTSH 1998
- ONC N/A
- Fundamental
- Price
- CTSH $72.37
- ONC $313.67
- Analyst Decision
- CTSH Buy
- ONC Strong Buy
- Analyst Count
- CTSH 16
- ONC 9
- Target Price
- CTSH $86.60
- ONC $335.78
- AVG Volume (30 Days)
- CTSH 4.5M
- ONC 410.3K
- Earning Date
- CTSH 07-30-2025
- ONC 08-06-2025
- Dividend Yield
- CTSH 1.70%
- ONC N/A
- EPS Growth
- CTSH 12.27
- ONC N/A
- EPS
- CTSH 4.93
- ONC N/A
- Revenue
- CTSH $20,486,000,000.00
- ONC $4,562,002,000.00
- Revenue This Year
- CTSH $7.66
- ONC $865.19
- Revenue Next Year
- CTSH $4.65
- ONC $21.12
- P/E Ratio
- CTSH $14.77
- ONC N/A
- Revenue Growth
- CTSH 6.34
- ONC 47.33
- 52 Week Low
- CTSH $65.52
- ONC $170.99
- 52 Week High
- CTSH $90.82
- ONC $330.63
- Technical
- Relative Strength Index (RSI)
- CTSH 50.66
- ONC 61.68
- Support Level
- CTSH $69.84
- ONC $301.33
- Resistance Level
- CTSH $71.70
- ONC $330.63
- Average True Range (ATR)
- CTSH 1.45
- ONC 9.12
- MACD
- CTSH 0.45
- ONC -0.19
- Stochastic Oscillator
- CTSH 85.99
- ONC 66.43
About CTSH Cognizant Technology Solutions Corporation
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 350,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.